Table 5 Characteristics of CMV-treated and CMV-untreated patients.

From: Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study

 

CMV-treated patients (n = 53)

CMV-untreated patients (n = 32)

p value

Age, mean ± SD, years

73.7 ± 11.5

67.1 ± 19.1

0.0492

Female, n (%)

40 (75.5%)

25 (78.1%)

< 0.0001

Neutrophil count, mean ± SD, /μL

7116 ± 4102

6154 ± 2915

0.2525

Lymphocyte count, mean ± SD, /μL

640 ± 492

708 ± 549

0.5596

Hemoglobin level, mean ± SD, g/dL

10.7 ± 1.9

10.6 ± 2.3

0.8380

Platelet count, mean ± SD, /μL

181,000 ± 148,000

182,000 ± 87,000

0.9610

C-reactive protein level, mean ± SD, mg/dL

2.7 ± 4.7

2.9 ± 4.4

0.8406

Aspartate aminotransferase level, mean ± SD, IU/L

36.6 ± 54.4

24.8 ± 13.0

0.2318

Alanine aminotransferase level, mean ± SD, IU/L

50.9 ± 89.3

32.2 ± 30.4

0.2537

Creatinine level, mean ± SD, mg/dL

0.9 ± 0.8

1.1 ± 1.2

0.4516

Immunoglobulin G level, mean ± SD, mg/dL

1192 ± 906.4

976 ± 308.2

0.5249

Back to article page